PDCD1 and cancer: Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein-1 (anti-PD-1) and anti-PD ligand-1 (anti-PD-L1) therapy have changed the treatment landscape of many cancer types, including EC (3).